ClinicalTrialsFinder

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) Clinical Trials in Seoul

1 recruitingSeoul, South Korea

Showing 1–1 of 1 trials

Recruiting
Phase 2

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
Yonsei University141 enrolled1 locationNCT06837792